Pharmaceutical scale is best understood through a combination of market value, drug revenue and pipeline depth. Eli Lilly and Novo Nordisk have risen sharply in market value as demand for GLP-1 obesity and diabetes treatments expanded. Johnson & Johnson, Merck, AbbVie, Roche, AstraZeneca, Novartis and Pfizer remain major global groups with broader portfolios.
Unlike software, pharmaceutical growth is built around patents and product cycles. A single successful drug can add billions of dollars in annual sales, but patent expiry can remove those economics surprisingly quickly. That makes research pipelines and lifecycle management central to valuation.
Obesity medicines changed the sector's centre of gravity
Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy created one of the most important pharmaceutical markets of the decade. Investors have focused not only on current prescriptions but on manufacturing capacity, new indications and the prospect of oral treatments.
The opportunity is large, but expectations are already reflected in valuations. Manufacturing execution, competition and reimbursement policy can therefore move the stocks even when underlying demand remains strong.
Oncology remains a major earnings engine
Merck's Keytruda is one of the world's most commercially important cancer medicines, while AstraZeneca, Roche, Bristol Myers Squibb and Novartis all maintain extensive oncology portfolios. Cancer treatment is attractive commercially because successful drugs can address multiple tumour types and combination regimens.
The investment risk is concentration. Companies must replace large products before patent protection weakens. That is why acquisition strategy and late-stage clinical data often matter as much as quarterly sales growth.
Diversification can reduce product risk
Johnson & Johnson combines pharmaceuticals with medical technology. Roche has diagnostics alongside medicines. Sanofi, GSK and Pfizer retain important vaccine businesses. AbbVie built a large immunology franchise and used acquisitions to broaden its pipeline as Humira lost exclusivity.
Diversification does not remove patent risk, but it can make earnings less dependent on one therapeutic area. Investors should still look at how much revenue comes from the top three products and how soon those products face generic or biosimilar competition.
How to compare pharmaceutical stocks
Market capitalisation is a useful starting point, but pipeline quality, patent duration, operating margin and research productivity are more informative for long-term returns. Free cash flow also matters because large pharmaceutical companies return significant capital through dividends and buybacks while funding acquisitions.
Clinical trial results introduce another layer of uncertainty. A late-stage failure can erase years of expected revenue in a day. That is why even the largest pharmaceutical groups require a portfolio view rather than analysis based on one headline product.